Clinical Trial Update: Bortezomib in Intrahepatic Cholangiocellular Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating bortezomib in intrahepatic cholangiocarcinoma; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• Bortezomib (bortezomib)

Snippet

Sponsor: Zhengang Yuan | Conditions: Intrahepatic Cholangiocarcinoma | Phase 3 | Status: UNKNOWN